- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02949999
Voclosporin in Healthy Japanese Volunteers
January 12, 2018 updated by: Aurinia Pharmaceuticals Inc.
A Single-center, Double-blind, Placebo-controlled, Randomized, Ascending Multiple-dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of Voclosporin in Healthy Japanese Volunteers
The study is a single-centre, double-blind, placebo controlled, randomized, ascending multiple dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamic profiles of voclosporin.
Study Overview
Detailed Description
Ten subjects will be randomized into each of four treatment groups to receive approximately 0.25, 0.5, 1.0, 1.5mg/kg/dose of voclosporin vs placebo.
For Day 1, subjects will be given oral treatment once a day; Day 2, subjects will not be given any oral treatment; Day 3-12, subjects will be given oral treatment twice a day; Day 13, subjects will be given oral treatment once a day.
The duration of the study takes about 21 days (including follow up assessments).
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Cavite
-
Dasmarinas City, Cavite, Philippines
- MAD VCS Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 45 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Key Inclusion Criteria:
- Japanese males and females by birth aged 20 - 45 years inclusive
- Females who are non-pregnant, non-lactating, and either post-menopausal for at least 1 year, surgically sterile for at least 3 months, or from 35 days prior to study entry (i.e. Day -2) until 30 days following study completion/discharge and using an approved method of contraception.
- Males who are sterile or from the time of dose administration until 30 days following their dose administration and using an approved method of contraception.
- Screening FSH >40 IU/ml in self-identified post-menopausal female subjects.
- Weight must be >55 kg but <100 kg, with BMI of 18-30 kg/m2 inclusive.
- Healthy as defined by normal screening assessments, including full medical history, complete physical examination, vital signs, 12-lead ECG, hematology, blood chemistry and urinalysis. Laboratory results must be within the reference range or considered to be not clinically significant by the Principal Investigator with agreement of the Medical Monitor. Lab tests may be repeated during the screening period as appropriate.
- Capable to participate, provide informed consent and comply with study procedures and restrictions
- Must agree to refrain from consumption of grapefruit juice from at least one week prior to dosing until all follow-up procedures are completed.
Key Exclusion Criteria:
- History of drug abuse and/or alcoholism in the previous 2 years.
- Positive urine drug test, urine cotinine test or alcohol breath test at screening.
- Positive for Hepatitis B, Hepatitis C or HIV.
- QTcB >430 msec in males, or QTcB >450 msec in females in 12-lead ECG tracing at screening.
- Blood donation within 56 days prior to dosing and plasma donation within 7 days prior to first dosing.
- Hemoglobin value < 12 g/dL.
- Current smokers (smoking cigarettes and other forms of tobacco or nicotine use must be stopped at least 90 days before screening).
- History of alcohol consumption averaging more than 2 drinks per day in a week (1 drink is 12 oz beer, 4 oz wine or 1.5oz of spirits) within 6 months prior to screening. Alcohol-containing foods or beverages are prohibited within 7 days prior to study entry and during the entire study duration.
- Use of any drugs known to inhibit or induce hepatic drug metabolism (i.e. inducers include barbiturates, carbamazepine, phenytoin, glucocorticoids, rifampin/rifabutin; inhibitors include antidepressants, cimetidine, diltiazem, erythromycin, ketoconazole, MAO inhibitors, neuroleptics, verapamil, quinidine) within 30 days prior to administration of the study medication.
- Participation in a clinical trial involving the administration of an investigational or marketed drug within 30 days (90 days for biologics) prior to the first dosing
- Use of prescription medication within 14 days prior to first dosing or over-the-counter products (including natural products, vitamins, garlic as supplement) within 7 days prior to first dosing, except for topical products without systemic absorption, or is likely to need medication during the study period.
- Clinically significant abnormal liver function, abnormal renal function, active tuberculosis (TB), or known history of TB/evidence of old TB if not taking prophylaxis with isoniazid, current or recent infections, history of hypertension and history of malignancy.
- Any reason which, in the opinion of the Principal Investigator or the Sponsor's medical monitor, would prevent the subject from participating in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 0.25mg/kg voclosporin
0.25mg/kg voclosporin BID.
|
Other Names:
|
EXPERIMENTAL: 0.5mg/kg voclosporin
0.5mg/kg voclosporin BID
|
Other Names:
|
EXPERIMENTAL: 1.0mg/kg voclosporin
1.0mg/kg voclosporin BID
|
Other Names:
|
EXPERIMENTAL: 1.5mg/kg voclosporin
1.5mg/kg voclosporin BID
|
Other Names:
|
PLACEBO_COMPARATOR: Placebo voclosporin
placebo BID
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment emergent adverse events
Time Frame: 21 days
|
Tolerability of voclosporin after single and multiple oral ascending doses
|
21 days
|
Mean, median and standard deviation of laboratory parameters. Incidence of laboratory parameters outside of normal range
Time Frame: 21 days
|
Safety of voclosporin after single and multiple oral ascending doses
|
21 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics of voclosporin after single and multiple oral ascending doses
Time Frame: 21 days
|
Peak Plasma Concentration (Cmax)
|
21 days
|
Pharmacokinetics of voclosporin after single and multiple oral ascending doses
Time Frame: 21 days
|
Area under the plasma concentration versus time curve (AUC)
|
21 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2016
Primary Completion (ACTUAL)
December 1, 2016
Study Completion (ACTUAL)
December 1, 2016
Study Registration Dates
First Submitted
October 20, 2016
First Submitted That Met QC Criteria
October 27, 2016
First Posted (ESTIMATE)
October 31, 2016
Study Record Updates
Last Update Posted (ACTUAL)
January 17, 2018
Last Update Submitted That Met QC Criteria
January 12, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- AUR-VCS-2015-J01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Volunteers
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
University Hospital, Clermont-FerrandInstitut de Médecine du Travail; UMR CNRS 6024, LaPSCoRecruiting
-
McMaster UniversityOntario Ministry of Health and Long Term Care; Canadian Red Cross; David BraleyCompleted
-
Medtronic Cardiac Rhythm and Heart FailureCompleted
Clinical Trials on Voclosporin
-
Weill Medical College of Cornell UniversityAvailableImmunosuppression | Transplantation, KidneyUnited States
-
Aurinia Pharmaceuticals Inc.United BioSource, LLCRecruiting
-
Aurinia Pharmaceuticals Inc.CompletedLupus NephritisUnited States, Argentina, Belarus, Brazil, Bulgaria, Canada, Chile, Colombia, Costa Rica, Croatia, Dominican Republic, Guatemala, Japan, Korea, Republic of, Malaysia, Mexico, Netherlands, North Macedonia, Peru, Philippines, Poland, Puerto Rico and more
-
Aurinia Pharmaceuticals Inc.Completed
-
Aurinia Pharmaceuticals Inc.TerminatedFocal Segmental GlomerulosclerosisUnited States, Dominican Republic
-
Aurinia Pharmaceuticals Inc.Completed
-
Aurinia Pharmaceuticals Inc.Completed
-
Aurinia Pharmaceuticals Inc.Labcorp Drug Development IncRecruiting
-
Aurinia Pharmaceuticals Inc.CompletedLupus NephritisUnited States
-
Aurinia Pharmaceuticals Inc.Labcorp Corporation of America Holdings, IncNot yet recruitingAdolescent Lupus NephritisUnited States